Mortality is not increased in SARS‐CoV‐2 infected persons with hepatitis C virus infection
Background Impact of SARS‐CoV‐2 infection upon hospitalization, intensive care unit (ICU) admissions and mortality in persons with hepatitis C virus (HCV) infection is unknown. Methods We used the Electronically Retrieved Cohort of HCV infected Veterans (ERCHIVES) database to determine the impact of...
Gespeichert in:
| Veröffentlicht in: | Liver international 2021-08, Vol.41 (8), p.1824-1831 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1831 |
|---|---|
| container_issue | 8 |
| container_start_page | 1824 |
| container_title | Liver international |
| container_volume | 41 |
| creator | Butt, Adeel A. Yan, Peng Chotani, Rashid A. Shaikh, Obaid S. |
| description | Background
Impact of SARS‐CoV‐2 infection upon hospitalization, intensive care unit (ICU) admissions and mortality in persons with hepatitis C virus (HCV) infection is unknown.
Methods
We used the Electronically Retrieved Cohort of HCV infected Veterans (ERCHIVES) database to determine the impact of HCV infection upon the rates of acute care hospitalization, ICU admission and all‐cause mortality. We identified Veterans with chronic HCV infection and propensity score matched controls without HCV in ERCHIVES. We excluded those with HIV or hepatitis B virus coinfection.
Results
We identified 975 HCV+ and 975 propensity score matched HCV− persons with SARS‐CoV‐2 infection. Mean FIB‐4 score (±SD) was higher in those with HCV (1.9 ± 2.1 vs 1.2 ± 0.9; P |
| doi_str_mv | 10.1111/liv.14804 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8013466</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2486463501</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4434-59502550042dab90cb76421a6e92c8530951ed363323ec61a81e1efa9d55e1643</originalsourceid><addsrcrecordid>eNp1kctKAzEUhoMoXqoLX0AG3OiimntnNoIUb1ARvC0NaebURqaTmmQq3fkIPqNPYrS1qGAWySHnOz_n50dom-ADks5hZScHhOeYL6F1wjt5m1FGlhc1ZWtoI4QnjElRCLKK1hgTjBeMrKOHS-ejrmycZjZktYuZrY0HHaBMVXZzfH3z_vrWdffppulnACam1hh8cHXIXmwcZkMY62hjmu9mE-ubMOesqzfRykBXAbbmbwvdnZ7cds_bvauzi-5xr204Z7wtCoGpEBhzWup-gU2_IzklWkJBTS4YTmtDySRLxsBIonMCBAa6KIUAIjlroaOZ7rjpj6A0UEevKzX2dqT9VDlt1e9ObYfq0U1UjgnjUiaBvbmAd88NhKhGNhioKl2Da4KiPJdcMpHwFtr9gz65xtfJnkoeKM07VHYStT-jjHcheBgsliFYfaamUmrqK7XE7vzcfkF-x5SAwxnwYiuY_q-kehf3M8kPMbqicQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2552287267</pqid></control><display><type>article</type><title>Mortality is not increased in SARS‐CoV‐2 infected persons with hepatitis C virus infection</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Butt, Adeel A. ; Yan, Peng ; Chotani, Rashid A. ; Shaikh, Obaid S.</creator><creatorcontrib>Butt, Adeel A. ; Yan, Peng ; Chotani, Rashid A. ; Shaikh, Obaid S.</creatorcontrib><description>Background
Impact of SARS‐CoV‐2 infection upon hospitalization, intensive care unit (ICU) admissions and mortality in persons with hepatitis C virus (HCV) infection is unknown.
Methods
We used the Electronically Retrieved Cohort of HCV infected Veterans (ERCHIVES) database to determine the impact of HCV infection upon the rates of acute care hospitalization, ICU admission and all‐cause mortality. We identified Veterans with chronic HCV infection and propensity score matched controls without HCV in ERCHIVES. We excluded those with HIV or hepatitis B virus coinfection.
Results
We identified 975 HCV+ and 975 propensity score matched HCV− persons with SARS‐CoV‐2 infection. Mean FIB‐4 score (±SD) was higher in those with HCV (1.9 ± 2.1 vs 1.2 ± 0.9; P < .0001) and a larger proportion of those with HCV had cirrhosis (8.1% vs 1.4%; P < .0001). A larger proportion of HCV+ were hospitalized compared to HCV‐ (24.0% vs 18.3%; P = .002); however, those requiring ICU care and mortality were also similar in both groups (6.6% vs 6.5%; P = .9). Among those with FIB‐4 score of 1.45‐3.25, hospitalization rate/1000‐person‐years was 41.4 among HCV+ and 20.2 among HCV−, while among those with a FIB‐4 > 3.25, the rate‐ was 9.4 and 0.6 (P < .0001). There was no difference in all‐cause mortality by age, gender, FIB‐4 score, number of comorbidities or treatment with remdesivir and/or systemic corticosteroids.
Conclusions
HCV+ persons with SARS‐CoV‐2 infection are more likely to be admitted to a hospital. The hospitalization rate also increased with higher FIB‐4 score. However, admission to an ICU and mortality are not different between those with and without HCV infection.</description><identifier>ISSN: 1478-3223</identifier><identifier>EISSN: 1478-3231</identifier><identifier>DOI: 10.1111/liv.14804</identifier><identifier>PMID: 33534931</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Chronic infection ; Cirrhosis ; Corticoids ; Corticosteroids ; COVID‐19 ; ERCHIVES ; Hepatitis ; Hepatitis B ; Hepatitis C ; hepatitis C virus ; HIV ; Hospitalization ; Human immunodeficiency virus ; Infections ; Liver cirrhosis ; liver fibrosis ; Mortality ; Original ; Public health ; SARS‐CoV‐2 ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; Viral diseases ; Viral Hepatitis ; Viruses</subject><ispartof>Liver international, 2021-08, Vol.41 (8), p.1824-1831</ispartof><rights>2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><rights>2021 John Wiley & Sons A/S</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4434-59502550042dab90cb76421a6e92c8530951ed363323ec61a81e1efa9d55e1643</citedby><cites>FETCH-LOGICAL-c4434-59502550042dab90cb76421a6e92c8530951ed363323ec61a81e1efa9d55e1643</cites><orcidid>0000-0002-1118-1826</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fliv.14804$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fliv.14804$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,777,781,882,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33534931$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Butt, Adeel A.</creatorcontrib><creatorcontrib>Yan, Peng</creatorcontrib><creatorcontrib>Chotani, Rashid A.</creatorcontrib><creatorcontrib>Shaikh, Obaid S.</creatorcontrib><title>Mortality is not increased in SARS‐CoV‐2 infected persons with hepatitis C virus infection</title><title>Liver international</title><addtitle>Liver Int</addtitle><description>Background
Impact of SARS‐CoV‐2 infection upon hospitalization, intensive care unit (ICU) admissions and mortality in persons with hepatitis C virus (HCV) infection is unknown.
Methods
We used the Electronically Retrieved Cohort of HCV infected Veterans (ERCHIVES) database to determine the impact of HCV infection upon the rates of acute care hospitalization, ICU admission and all‐cause mortality. We identified Veterans with chronic HCV infection and propensity score matched controls without HCV in ERCHIVES. We excluded those with HIV or hepatitis B virus coinfection.
Results
We identified 975 HCV+ and 975 propensity score matched HCV− persons with SARS‐CoV‐2 infection. Mean FIB‐4 score (±SD) was higher in those with HCV (1.9 ± 2.1 vs 1.2 ± 0.9; P < .0001) and a larger proportion of those with HCV had cirrhosis (8.1% vs 1.4%; P < .0001). A larger proportion of HCV+ were hospitalized compared to HCV‐ (24.0% vs 18.3%; P = .002); however, those requiring ICU care and mortality were also similar in both groups (6.6% vs 6.5%; P = .9). Among those with FIB‐4 score of 1.45‐3.25, hospitalization rate/1000‐person‐years was 41.4 among HCV+ and 20.2 among HCV−, while among those with a FIB‐4 > 3.25, the rate‐ was 9.4 and 0.6 (P < .0001). There was no difference in all‐cause mortality by age, gender, FIB‐4 score, number of comorbidities or treatment with remdesivir and/or systemic corticosteroids.
Conclusions
HCV+ persons with SARS‐CoV‐2 infection are more likely to be admitted to a hospital. The hospitalization rate also increased with higher FIB‐4 score. However, admission to an ICU and mortality are not different between those with and without HCV infection.</description><subject>Chronic infection</subject><subject>Cirrhosis</subject><subject>Corticoids</subject><subject>Corticosteroids</subject><subject>COVID‐19</subject><subject>ERCHIVES</subject><subject>Hepatitis</subject><subject>Hepatitis B</subject><subject>Hepatitis C</subject><subject>hepatitis C virus</subject><subject>HIV</subject><subject>Hospitalization</subject><subject>Human immunodeficiency virus</subject><subject>Infections</subject><subject>Liver cirrhosis</subject><subject>liver fibrosis</subject><subject>Mortality</subject><subject>Original</subject><subject>Public health</subject><subject>SARS‐CoV‐2</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Viral diseases</subject><subject>Viral Hepatitis</subject><subject>Viruses</subject><issn>1478-3223</issn><issn>1478-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp1kctKAzEUhoMoXqoLX0AG3OiimntnNoIUb1ARvC0NaebURqaTmmQq3fkIPqNPYrS1qGAWySHnOz_n50dom-ADks5hZScHhOeYL6F1wjt5m1FGlhc1ZWtoI4QnjElRCLKK1hgTjBeMrKOHS-ejrmycZjZktYuZrY0HHaBMVXZzfH3z_vrWdffppulnACam1hh8cHXIXmwcZkMY62hjmu9mE-ubMOesqzfRykBXAbbmbwvdnZ7cds_bvauzi-5xr204Z7wtCoGpEBhzWup-gU2_IzklWkJBTS4YTmtDySRLxsBIonMCBAa6KIUAIjlroaOZ7rjpj6A0UEevKzX2dqT9VDlt1e9ObYfq0U1UjgnjUiaBvbmAd88NhKhGNhioKl2Da4KiPJdcMpHwFtr9gz65xtfJnkoeKM07VHYStT-jjHcheBgsliFYfaamUmrqK7XE7vzcfkF-x5SAwxnwYiuY_q-kehf3M8kPMbqicQ</recordid><startdate>202108</startdate><enddate>202108</enddate><creator>Butt, Adeel A.</creator><creator>Yan, Peng</creator><creator>Chotani, Rashid A.</creator><creator>Shaikh, Obaid S.</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1118-1826</orcidid></search><sort><creationdate>202108</creationdate><title>Mortality is not increased in SARS‐CoV‐2 infected persons with hepatitis C virus infection</title><author>Butt, Adeel A. ; Yan, Peng ; Chotani, Rashid A. ; Shaikh, Obaid S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4434-59502550042dab90cb76421a6e92c8530951ed363323ec61a81e1efa9d55e1643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Chronic infection</topic><topic>Cirrhosis</topic><topic>Corticoids</topic><topic>Corticosteroids</topic><topic>COVID‐19</topic><topic>ERCHIVES</topic><topic>Hepatitis</topic><topic>Hepatitis B</topic><topic>Hepatitis C</topic><topic>hepatitis C virus</topic><topic>HIV</topic><topic>Hospitalization</topic><topic>Human immunodeficiency virus</topic><topic>Infections</topic><topic>Liver cirrhosis</topic><topic>liver fibrosis</topic><topic>Mortality</topic><topic>Original</topic><topic>Public health</topic><topic>SARS‐CoV‐2</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Viral diseases</topic><topic>Viral Hepatitis</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Butt, Adeel A.</creatorcontrib><creatorcontrib>Yan, Peng</creatorcontrib><creatorcontrib>Chotani, Rashid A.</creatorcontrib><creatorcontrib>Shaikh, Obaid S.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Liver international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Butt, Adeel A.</au><au>Yan, Peng</au><au>Chotani, Rashid A.</au><au>Shaikh, Obaid S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mortality is not increased in SARS‐CoV‐2 infected persons with hepatitis C virus infection</atitle><jtitle>Liver international</jtitle><addtitle>Liver Int</addtitle><date>2021-08</date><risdate>2021</risdate><volume>41</volume><issue>8</issue><spage>1824</spage><epage>1831</epage><pages>1824-1831</pages><issn>1478-3223</issn><eissn>1478-3231</eissn><abstract>Background
Impact of SARS‐CoV‐2 infection upon hospitalization, intensive care unit (ICU) admissions and mortality in persons with hepatitis C virus (HCV) infection is unknown.
Methods
We used the Electronically Retrieved Cohort of HCV infected Veterans (ERCHIVES) database to determine the impact of HCV infection upon the rates of acute care hospitalization, ICU admission and all‐cause mortality. We identified Veterans with chronic HCV infection and propensity score matched controls without HCV in ERCHIVES. We excluded those with HIV or hepatitis B virus coinfection.
Results
We identified 975 HCV+ and 975 propensity score matched HCV− persons with SARS‐CoV‐2 infection. Mean FIB‐4 score (±SD) was higher in those with HCV (1.9 ± 2.1 vs 1.2 ± 0.9; P < .0001) and a larger proportion of those with HCV had cirrhosis (8.1% vs 1.4%; P < .0001). A larger proportion of HCV+ were hospitalized compared to HCV‐ (24.0% vs 18.3%; P = .002); however, those requiring ICU care and mortality were also similar in both groups (6.6% vs 6.5%; P = .9). Among those with FIB‐4 score of 1.45‐3.25, hospitalization rate/1000‐person‐years was 41.4 among HCV+ and 20.2 among HCV−, while among those with a FIB‐4 > 3.25, the rate‐ was 9.4 and 0.6 (P < .0001). There was no difference in all‐cause mortality by age, gender, FIB‐4 score, number of comorbidities or treatment with remdesivir and/or systemic corticosteroids.
Conclusions
HCV+ persons with SARS‐CoV‐2 infection are more likely to be admitted to a hospital. The hospitalization rate also increased with higher FIB‐4 score. However, admission to an ICU and mortality are not different between those with and without HCV infection.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>33534931</pmid><doi>10.1111/liv.14804</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-1118-1826</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-3223 |
| ispartof | Liver international, 2021-08, Vol.41 (8), p.1824-1831 |
| issn | 1478-3223 1478-3231 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8013466 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Chronic infection Cirrhosis Corticoids Corticosteroids COVID‐19 ERCHIVES Hepatitis Hepatitis B Hepatitis C hepatitis C virus HIV Hospitalization Human immunodeficiency virus Infections Liver cirrhosis liver fibrosis Mortality Original Public health SARS‐CoV‐2 Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Viral diseases Viral Hepatitis Viruses |
| title | Mortality is not increased in SARS‐CoV‐2 infected persons with hepatitis C virus infection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T12%3A28%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mortality%20is%20not%20increased%20in%20SARS%E2%80%90CoV%E2%80%902%20infected%20persons%20with%20hepatitis%20C%20virus%20infection&rft.jtitle=Liver%20international&rft.au=Butt,%20Adeel%20A.&rft.date=2021-08&rft.volume=41&rft.issue=8&rft.spage=1824&rft.epage=1831&rft.pages=1824-1831&rft.issn=1478-3223&rft.eissn=1478-3231&rft_id=info:doi/10.1111/liv.14804&rft_dat=%3Cproquest_pubme%3E2486463501%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2552287267&rft_id=info:pmid/33534931&rfr_iscdi=true |